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Short Communication
Human β-defensin 3 increases the TLR9-dependent
response to bacterial DNA
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Human β-defensin 3 (hBD3) is a cationic antimicrobial peptide with potent bactericidal
activity in vitro. HBD3 is produced in response to pathogen challenge and can modu-
late immune responses. The amplified recognition of self-DNA by human plasmacytoid
dendritic cells has been previously reported, but we show here that hBD3 preferentially
enhances the response to bacterial DNA inmouse Flt-3 induced dendritic cells (FLDCs) and
in human peripheral blood mononuclear cells. We show the effect is mediated through
TLR9 and although hBD3 significantly increases the cellular uptake of both E. coli and
self-DNA in mouse FLDCs, only the response to bacterial DNA is enhanced. Liposome
transfection also increases uptake of bacterial DNA and amplifies the TLR9-dependent
response. In contrast to hBD3, lipofection of self-DNA enhances inflammatory signaling,
but the response is predominantly TLR9-independent. Together, these data show that
hBD3 has a role in the innate immune-mediated response to pathogen DNA, increas-
ing inflammatory signaling and promoting activation of the adaptive immune system
via antigen presenting cells including dendritic cells. Therefore, our data identify an
additional immunomodulatory role for this copy-number variable defensin, of relevance
to host defence against infection and indicate a potential for the inclusion of HBD3 in
pathogen DNA-based vaccines.
Keywords: Antimicrobial peptide  β-Defensin  Dendritic cells  Plasmacytoid dendritic cells 
Toll like receptor 9  Type I interferon
 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
Antimicrobial peptides (AMP) such as defensins and the cathe-
licidin LL-37 were initially characterized as potent bactericidal
agents in vitro. AMP are now also recognized as important
immunomodulatory molecules, hence the term host defence pep-
tide (HDP) is now widely used [1, 2]. HDP are cationic peptides
Correspondence: Dr. Julia R. Dorin
e-mail: julia.dorin@ed.ac.uk
with amphipathic structures enabling them to rapidly enter cells
[3–5]. The expression of β-defensins at mucosal surfaces is min-
imal until triggered by pathogen- or damage-associated molec-
ular patterns (PAMP/DAMP) or inflammation [6, 7]. HDP have
been shown to modulate the host responses to nucleic acids.
Both LL-37 and human β-defensin 3 (hBD3) have been shown
to amplify the type I interferon response to viral dsRNA, via
the MAVS pathway in keratinocytes, and through MDA5/MAVS
in macrophages [3, 8]. LL-37, complexed with endogenous self-
DNA, enhances activation of the cytoplasmic pattern recognition
receptor stimulator of interferon genes in monocytes and TLR9 in
C© 2017 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim.
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human plasmacytoid dendritic cells (pDCs), resulting in a signifi-
cant increase in production of the type I interferon, IFN-α [9]. Sim-
ilarly, hBD3 has recently been shown to precipitate condensation
of human self-DNA, increasing its entry into pDCs and triggering
IFN-α production [10]. Furthermore, hBD2 and hBD3 can enhance
the uptake of self-DNA and promote DNA-induced IFN-α expres-
sion in human pDCs [11]. These immunomodulatory properties
of HDP have implicated their involvement in the pathogenesis of
autoimmune diseases including psoriasis, systemic lupus erythe-
matous, and type I diabetes [10, 12, 13]. Increased copy number
of the hyper copy number variable human β-defensin locus has
been associated with psoriasis [14]. However, bacterial infection
is a relatively common occurrence compared to development of
autoimmune disease. This highlights the importance of investigat-
ing the previously undescribed effect of hBD3 on the response to
bacterial DNA. Production of hBD3 at the site of infection results in
bacterial cell wall disruption and osmotic lysis, leading to release
of cytoplasmic contents, including DNA [15, 16]. The increased
response of antigen presenting cells to pathogen DNA in the pres-
ence of hBD3 would promote the functional activation of other
immune cells involved in host defence. Therefore, we sought to
determine the cellular response of mouse and human antigen pre-
senting cells to bacterial DNA in the presence of hBD3 as would
be encountered in an infection setting.
We show here that hBD3 significantly amplified the response to
bacterial DNA in both mouse and human immune cells in a TLR9-
dependent manner. This demonstrates a further important aspect
of protection from infection afforded by defensins and suggests
that this property of hBD3 could be utilized to increase efficacy of
DNA-based vaccines.
Results and discussion
hBD3 enhances the immune response to bacterial
DNA in murine FLDCs and human PBMCs
The effect of hBD3 on the immune response to bacterial DNA, such
as would be released by AMP-mediated killing during infection
was investigated in murine Flt-3 ligand-induced bone marrow-
derived dendritic cell cultures (FLDCs), comprising a mixed popu-
lation of conventional DCs (cDCs) and plasmacytoid DCs (pDCs).
FLDCs have beenwidely used to study the innate immune response
to nucleic acids [11, 17, 18]. cDCs and pDCs are identifiable by
expression of CD11c and B220 and activation of the populations
can be independently assessed (Supporting Information Fig. 1).
pDCs (CD11c+ B220high), constitute approximately 10–20% of
FLDCs and are specialized to rapidly produce large amounts of
IFN-α in response to particular immune stimuli, due to increased
expression and rapid activation of the transcription factor IFN
regulatory factor 7, by a pDC-specific MyD88-dependent path-
way [19, 20].
As expected, treatment of murine FLDCs with 1 μg/mL E. coli-
DNA resulted in upregulation of costimulatory molecules and pro-
duction of IFN-α and IL-6 (Fig. 1A and B). We confirmed that
the response to E. coli-DNA was not caused by another bacte-
rial contaminant in the DNA preparation (Supporting Information
Fig. 2).
HBD3 alone had no effect on cytokine expression, cell surface
marker expression or viability of FLDCs at the concentration used
throughout this study (Supporting Information Fig. 3). However,
5 μg/mL hBD3 (1 μM) in combination with E. coli-DNA resulted in
a significant increase in the production of IFN-α and IL-6 and the
expression of costimulatory molecules by murine FLDCs compared
with bacterial DNA alone (Fig. 1A and B and Supporting Infor-
mation Fig. 4). We additionally show that hBD3 combined with
bacterial DNA, significantly increased the production of CXCL10
(a cytokine induced by type I interferon and reflects activation
of pDCs [21]) by human ex vivo PBMCs (Fig. 1C). It is therefore
likely that the bacterial DNA-induced cytokine release we observe
in human (as in mouse) is due to TLR9 activation of pDCs in the
total PBMC population. This has previously been shown with CpG
in human pDCs isolated from peripheral blood [22]. Human cDCs
do not express TLR9 [22] but other immune cells in human PBMCs
do express TLR9 (NK cells; B cells; CD4+ and CD8+ T cells and
predominantly CD14 monocytes [23]) and these may also be acti-
vated and contribute to the increased cytokine release we observe
with bacterial DNA in combination with hBD3.
hBD3 enhances the immune response to self-DNA
only in human PBMCs
It has been previously reported that self-DNA alone does not
induce any response in human pDCs. However liposome trans-
fection [24] or complexing to HDP (including hBD3) increases
the IFN-α response to self-DNA in human pDCs [10, 11]. Schmidt
et al. showed that various cationic molecules enable endosomal
localization of self-DNA, thereby increasing access to endosomal
TLR9 in human pDCs [25]. However only molecules of a certain
size enabled optimal inter-DNA spacing allowing multiple TLR9
interactions and activation that correlated with an increased inter-
feron response and hBD3 allowed optimal arrangement of DNA
ligand and human TLR9 [25]. In agreement with these publica-
tions, we see an increase in CXCL10 in human pDCs treated with
self-DNA and hBD3 compared to self-DNA alone. In contrast, in
mouse FLDCs, self-DNA did not stimulate an immune response
and hBD3 did not influence this (Fig. 1A–C). Defb14 is the clear
orthologue of DEFB103 (hBD3) despite being only 64% identi-
cal and we have previously demonstrated that its bactericidal and
chemoattractant abilities are fundamentally similar [26]. In addi-
tion, Barabas et al. have shown that mouse bone marrow derived
macrophages exposed to Defb14 reveal an exacerbated response
to various TLR ligands, including CpG that is known to activate
TLR9. This implies that the increased TLR9 response to bacterial
DNA by these defensin peptides is conserved between human and
mouse [27]. However, the species difference in the influence of
hBD3 on the response of pDCs to self-DNA may reflect the dif-
ferences between human and mouse in the ability of TLR9 to
recognize mammalian DNA [28].
C© 2017 The Authors. European Journal of Immunology published by
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Figure 1. hBD3 stimulates an increased inflamma-
tory response to bacterial DNA in mouse FLDCs and
human PBMCs. Mouse FLDCs were incubated with
E. coli- or self-DNA with or without hBD3. Cells and
supernatants were collected. IFN-α and IL-6 secretion
were assayed by ELISA (A) and costimulatory marker
expression was assayed in cDCs (CD11c+ B220−) and
pDCs (CD11c+ B220high) by flow cytometry (B). Data
are shown as mean ± SEM and are pooled from
three or more independent experiments performed
in triplicate. *p < 0.05, **p < 0.01 unpaired t-test.
Human PBMCs were extracted from peripheral blood
by Ficoll gradient centrifugation. PBMCs were imme-
diately incubated with E. coli- or self-DNA with or
without hBD3. Supernatants were harvested after 24
h and CXCL10measured by ELISA (C). Data are shown
asmean± SEM and are pooled from five independent
experiments with one donor sample per experiment.
*p < 0.05 paired t-test.
The increased immune response of FLDCs to bacterial
DNA in the presence of hBD3 is mediated by TLR9
We used TLR9−/− FLDCs to test whether the hBD3-mediated
amplification of the immune response of FLDCs to bacterial DNA
was due to increased activation of TLR9, or due to activation of an
alternative cytoplasmic pattern recognition receptor, as we have
previously shown with hBD3 and poly(I:C)) [3]. Endosomal TLR9
is activated by bacterial DNA due to the presence of unmethylated
CpG residues, and can also sense the phosphodiester DNA back-
bone of unmodified single-stranded DNA in a CpG-independent
manner [29, 30]. FLDCs treated with in vitro methylated
E. coli-DNA showed a significant reduction in the inflammatory
response compared to exposure to untreated E. coli-DNA (Sup-
porting Information Fig. 5) consistent with TLR9 involvement. In
addition, the cytokine response to bacterial DNA with or without
hBD3 was ablated in TLR9−/− FLDCs (Fig. 2A). These results con-
firm that the increased response of FLDCs to bacterial DNA when
in the presence of hBD3 is mediated through TLR9.
We showed that self-DNA could only stimulate an immune
response in FLDCs when transfected (Fig. 2B). This response
to transfected self-DNA was shown to be almost entirely TLR9-
independent implicating an alternative receptor in the response of
FLDCs to transfected self-DNA (Fig. 2B). This is in contrast, to the
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 2. The effect of hBD3 on the response to E. coli-DNA in mouse FLDCs is TLR9 dependent. Mouse FLDCs fromWT or TLR9 deficient (TLR9−/−)
mice were incubated with E. coli-DNA with or without hBD3. Supernatants were collected and cytokine secretion was assayed by ELISA (A). Mouse
FLDCs fromWT or TLR9 deficient (TLR9−/−) mice were incubated or transfected with E. coli- or self-DNA. Supernatants were collected and cytokine
secretion was assayed by ELISA (B). The response to TLR4 ligand LPS was intact in both WT and TLR9 –/–FLDC (and reduced in the presence of
hBD3 as expected [31](Supporting Information Fig.6), Data are shown as mean ± SEM and are pooled from three or more independent experiments
performed in triplicate. *p < 0.05, **p < 0.01 unpaired t-test.
response to transfected bacterial DNA, which was almost entirely
TLR9-dependent (Fig. 2B). These results firstly confirm that lipo-
fection transports DNA via the endosome since the response to
bacterial DNA is TLR9-dependent. Secondly, this demonstrates
that in murine FLDCs, self-DNA complexed with lipofectamine is
not recognized by TLR9, and likely activates a cytoplasmic DNA
receptor upon escape from the endosomal pathway.
hBD3 increases uptake of labeled E. coli-DNA and
self-DNA into FLDCs
We next sought to understand the mechanistic basis for the effect
of hBD3 on the response to bacterial DNA. An electrophoretic
mobility shift assay demonstrated that hBD3 prevented migration
of DNA into an agarose gel in concentration-dependent manner
(Supporting Information Fig. 7). This suggests that, in vitro, hBD3
causes DNA to aggregate into a complex large enough to prevent
migration into a gel.
We used fluorescently labeled E. coli-DNA to further inves-
tigate the effect hBD3 has on the cellular uptake of bacterial
DNA. Flow cytometry demonstrated that hBD3 increased uptake of
fluorescently labeled bacterial DNA by FLDCs, (Fig. 3A (MFI)).
Interestingly, the proportion of cells taking up fluorescently
labeled self-DNA was also significantly increased in the presence
of hBD3 (Fig. 3A (%Rhodamine+)) suggesting that, despite hBD3
increasing uptake of bacterial and self-DNA, self-DNA is intrinsi-
cally nonimmunogenic in mouse FLDCs and does not activate any
immune receptors in these cells.
We additionally observed by microscopy that hBD3 treatment
appeared to result in DNA aggregation in FLDCs compared with
a more diffuse pattern in the absence of hBD3 (Fig. 3C, white
arrows). This corresponds with the results from the gel shift assay.
These data indicate that hBD3 increases the response to E. coli-
DNA by increasing cellular uptake, leading to increased activa-
tion of TLR9 and a consequent increase in costimulatory marker
expression and cytokine production.
Concluding remarks
In summary, we show that in both mouse and human immune
cells the antimicrobial host defence peptide hBD3 amplifies
the response to bacterial DNA, eliciting increased expression of
C© 2017 The Authors. European Journal of Immunology published by
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Figure 3. hBD3 causes increased uptake of labeled E. coli- and self-DNA into mouse FLDCs and aggregation of DNA. Mouse FLDCs were incubated
or transfected with rhodamine-labeled E. coli-DNA or rhodamine-labeled self-DNAwith or without hBD3, or lipofection. Cell uptake was assayed by
flow cytometry. Representative flow plots show gating of Rhodamine+ cells. DNA uptake was quantified by measuring proportion of rhodamine+
cells and MFI following incubation of cells with labeled DNA and hBD3 (A) or lipofectamine. (B) Data are shown as mean ± SD and are pooled from
two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.005 unpaired t-test. Uptake of labeled E. coli-DNA was visualized by fluorescence and
differential interference contrast microscopy. White arrow indicates intracellular labeled E. coli-DNA, in contrast to white arrow head indicating
extracellular DNA (C). Scale bar = 400 μm. Images are from a single experiment representative of two independent experiments.
costimulatory markers and inflammatory cytokines, including type
I interferons. The hBD3 gene, DEFB103, is present in a highly copy
number variable locus in humans and copy number of this locus
correlates with systemic peptide expression [32]. Our work here
suggests that copy number may influence the individual’s response
to infection. Additionally, this work highlights future potential for
hBD3 as a TLR9 agonist for novel DNA-based vaccine therapeu-
tics, acting by sensitizing the immune response, particularly to
pathogen components.
Materials and methods
Antibodies and reagents
E. coli genomic DNA (InvivoGen) was used at 1 μg/mL. Mouse
genomic DNA was used at 1 μg/mL. hBD3 (Peptide Institute) was
used at 5 μg/mL. Lipofectamine LTX (ThermoFisher) was used as
per manufacturer’s instructions.
C© 2017 The Authors. European Journal of Immunology published by
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The following antibodies were used for flow cytometry:
CD11c-APC-eFluor780 (eBioscience), B220-eFluor450 (eBio-
science), CD80-APC (eBioscience), CD86-AlexaFluor488 (Biole-
gend), CD40-PE (BD Bioscience), MHCII-PerCP-Cy5.5 (Biole-
gend).
Murine IL-6 and human IP-10were quantified using Duoset kits
(R&D). Murine IFN-α was quantified using the following: Rat anti-
mouse IFN-α MAb (capture antibody), Rabbit anti-mouse IFN-α
PAb (detection antibody), Recombinant mouse IFN-α A (standard)
(all PBL Interferon Source), HRP-conjugated donkey anti-rabbit
(secondary antibody, Jackson Immunoresearch).
DNA was fluorescently labelled using the Label-IT nucleic acid
labeling kit (MirusBio).
Cell viability was measured by quantifying lactate dehydroge-
nase (LDH) activity in cell supernatants using an LDH-cytotoxicity
assay kit (Biovision).
The effect of hBD3 on migration of DNA into an agarose
gel was determined by incubating hBD3 and DNA and running
the entire reaction into a low percentage (0.5%) agarose gel
containing ethidium bromide. The gel was poststained with
Coomassie Blue.
FLDC isolation and culture
Bone marrow was extracted from the femurs of 8–12 week old
wild-type C57Bl6/J mice or TLR9−/− mice (with littermates as
controls) [29] and cultured with Flt-3L (200 ng/mL, Peprotech)
for 8 days. Animal studies were covered by a Project License,
granted by the UK Home Office under the Animal Scientific Pro-
cedures Act 1986, and locally approved by the University of Edin-
burgh Ethical Review Committee.
PBMC isolation
PBMCs were isolated from peripheral blood of adult donors
using Ficoll gradient and plated for immediate treatment. Human
venous blood was collected with written patient consent from
healthy volunteers according to Lothian Research Ethics Commit-
tee approvals under AMREC Reference number 15-HV-013.
Cell stimulation
Cells were harvested and plated at 2.5 × 106 cells/mL, and
incubated with ligands for 18–24 h. Supernatants were col-
lected for analysis by ELISA. Cells were collected and stained
for analysis by flow cytometry. Data were acquired using FACS
Aria II (BD Biosciences) and analyzed using FlowJo v 9/10.
For fluorescent microscopy, cells were treated for 4 h then har-
vested and attached to poly-lysine slides. Cells were fixed in
4% PFA and mounted using Vectashield with DAPI (VECTOR
laboratories).
Statistical tests
Unpaired Student’s t-tests were performed unless otherwise
stated, calculated using GraphPad Prism Software version 6/7 (La
Jolla, USA). Significance levels are denoted in figures as: *p 
0.05, **p  0.01, ***p  0.001, n.s. not significant.
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